U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H27NO2.ClH
Molecular Weight 313.8633
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VENLAFAXINE HYDROCHLORIDE

SMILES

CN(C)CC(c1ccc(cc1)OC)C2(CCCCC2)O.Cl

InChI

InChIKey=QYRYFNHXARDNFZ-UHFFFAOYSA-N
InChI=1S/C17H27NO2.ClH/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14;/h7-10,16,19H,4-6,11-13H2,1-3H3;1H

HIDE SMILES / InChI

Molecular Formula C17H27NO2
Molecular Weight 277.4024
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Venlafaxine is an arylalkanolamine serotonin-norepinephrine reuptake inhibitor, which is sold under several brand names; one of them is venlafaxine hydrochloride. Venlafaxine hydrochloride is a venlafaxine extended release tablets, which are indicated for the treatment of major depressive disorder (MDD). Efficacy of venlafaxine in MDD was shown in both short-term trials and a longer-term trial in MDD. A major depressive episode (DSM-IV) implies a prominent and relatively persistent depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period. In addition, venlafaxine hydrochloride is indicated for the treatment of social anxiety (SAD), also known as social phobia. Social Anxiety Disorder (DSM-IV) is characterized by a marked and persistent fear of 1 or more social or performance situations in which others expose to unfamiliar people or to possible scrutiny the person. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The mechanism of the antidepressant action of venlafaxine in humans is believed to be associated with its potentiation of neurotransmitter activity in the CNS. Preclinical studies have shown that venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake.

CNS Activity

Curator's Comment:: Known to be CNS penetrant in rat. Human data not available.

Originator

Curator's Comment:: Venlafaxine was first synthesized in the early 1980s by researchers at Wyeth Pharmaceuticals-- recognized venlafaxine’s promise as an important antidepressant and pressed forward with its development. Wyeth launched venlafaxine for the treatment of depression in the United States in early 1994 under the trade name Effexor. # Wyeth scientists: John Yardley, Morris Husbands, and Eric Muth

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.26 µM [Ki]
74.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VENLAFAXINE HYDROCHLORIDE

Approved Use

Major Depressive Disorder Venlafaxine Extended Release Tablets (venlafaxine hydrochloride) are indicated for the treatment of major depressive disorder (MDD). Efficacy of venlafaxine in MDD was shown in both short-term trials and a longer-term trial in MDD. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. Social Anxiety Disorder Venlafaxine Extended Release Tablets are indicated for the treatment of Social Anxiety Disorder (SAD), also known as Social Phobia, as defined in DSM-IV. Social Anxiety Disorder (DSM-IV) is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is a marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment.

Launch Date

1.21124159E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
260 ng/mL
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESVENLAFAXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
97.9 ng/mL
75 mg 1 times / day steady-state, oral
dose: 75 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESVENLAFAXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
26.9 ng/mL
75 mg 1 times / day steady-state, oral
dose: 75 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VENLAFAXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
150 ng/mL
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VENLAFAXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2926 ng × h/mL
75 mg 1 times / day steady-state, oral
dose: 75 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESVENLAFAXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
1536.3 ng × h/mL
75 mg 1 times / day steady-state, oral
dose: 75 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VENLAFAXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.5 h
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESVENLAFAXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
12.5 h
75 mg 1 times / day steady-state, oral
dose: 75 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESVENLAFAXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
7.5 h
75 mg 1 times / day steady-state, oral
dose: 75 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VENLAFAXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
10.7 h
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VENLAFAXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESVENLAFAXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
70%
75 mg 1 times / day steady-state, oral
dose: 75 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESVENLAFAXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
73%
75 mg 1 times / day steady-state, oral
dose: 75 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VENLAFAXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
73%
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VENLAFAXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Doses

Doses

DosePopulationAdverse events​
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Other AEs: Headache, Asthenia...
Other AEs:
Headache (34%)
Asthenia (17%)
Flu syndrome (6%)
Accidental injury (5%)
Abdominal pain (4%)
Hypertension (5%)
Vasodilatation (3%)
Palpitation (3%)
Nausea (29%)
Anorexia (20%)
Constipation (8%)
Diarrhea (6%)
Vomiting (3%)
Eructation (2%)
Weight loss (4%)
Insomnia (23%)
Dry mouth (17%)
Dizziness (16%)
Somnolence (16%)
Nervousness (11%)
Libido decreased (9%)
Anxiety (5%)
Agitation (4%)
Tremor (4%)
Abnormal dreams (4%)
Paresthesia (3%)
Twitching (2%)
Yawn (5%)
Sinusitis (2%)
Sweating (13%)
Abnormal vision (6%)
Abnormal ejaculation (16%)
Impotence (10%)
Orgasmic disorders and disturbances (8%)
Sources:
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Other AEs: Asthenia, Vasodilatation...
Other AEs:
Asthenia (8%)
Vasodilatation (4%)
Hypertension (4%)
Nausea (31%)
Constipation (8%)
Anorexia (8%)
Vomiting (4%)
Flatulence (4%)
Weight loss (3%)
Dizziness (20%)
Somnolence (17%)
Insomnia (17%)
Dry mouth (12%)
Nervousness (10%)
Abnormal dreams (7%)
Tremor (5%)
Depression (3%)
Paresthesia (3%)
Libido decreased (3%)
Agitation (3%)
Pharyngitis (7%)
Yawn (3%)
Sweating (14%)
Abnormal vision (4%)
Abnormal ejaculation (16%)
Impotence (4%)
Inhibited female orgasm (3%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Impotence 10%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Nervousness 11%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Sweating 13%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Abnormal ejaculation 16%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Dizziness 16%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Somnolence 16%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Asthenia 17%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Dry mouth 17%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Eructation 2%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Sinusitis 2%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Twitching 2%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Anorexia 20%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Insomnia 23%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Nausea 29%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Palpitation 3%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Paresthesia 3%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Vasodilatation 3%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Vomiting 3%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Headache 34%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Abdominal pain 4%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Abnormal dreams 4%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Agitation 4%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Tremor 4%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Weight loss 4%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Accidental injury 5%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Anxiety 5%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Hypertension 5%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Yawn 5%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Abnormal vision 6%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Diarrhea 6%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Flu syndrome 6%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Constipation 8%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Orgasmic disorders and disturbances 8%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Libido decreased 9%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 277
Health Status: unhealthy
Condition: Social Anxiety Disorder
Age Group: adult
Population Size: 277
Sources:
Nervousness 10%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Dry mouth 12%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Sweating 14%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Abnormal ejaculation 16%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Insomnia 17%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Somnolence 17%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Dizziness 20%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Agitation 3%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Depression 3%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Inhibited female orgasm 3%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Libido decreased 3%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Paresthesia 3%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Weight loss 3%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Yawn 3%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Nausea 31%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Abnormal vision 4%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Flatulence 4%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Hypertension 4%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Impotence 4%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Vasodilatation 4%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Vomiting 4%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Tremor 5%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Abnormal dreams 7%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Pharyngitis 7%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Anorexia 8%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Asthenia 8%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
Constipation 8%
225 mg 1 times / day multiple, oral
Recommended
Dose: 225 mg, 1 times / day
Route: oral
Route: multiple
Dose: 225 mg, 1 times / day
Sources:
unhealthy, adult
n = 357
Health Status: unhealthy
Condition: Major Depressive Disorder
Age Group: adult
Population Size: 357
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
minimal or no
minimal or no
minimal or no
no [IC50 >100 uM]
weak
yes (co-administration study)
Comment: info taken from abstract; Coadministration with risperidone increased AUC of risperidone by 32%. See https://pubmed.ncbi.nlm.nih.gov/24964257/
yes
yes
yes
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
inconclusive
yes (co-administration study)
Comment: Coadministration with ketoconazole (CYP3A4 inhibitor) increased AUC by 70%. See https://pubmed.ncbi.nlm.nih.gov/24964257/
Page: 7.0
no
yes
weak (co-administration study)
Comment: Coadministration with voriconazole (CYP2C9 inhibitor) increased AUC by 31%. See https://pubmed.ncbi.nlm.nih.gov/24964257/
yes
weak (co-administration study)
Comment: Coadministration with voriconazole (CYP2C9 inhibitor) increased AUC by 31%. See https://pubmed.ncbi.nlm.nih.gov/24964257/
yes
yes (co-administration study)
Comment: Coadministration with diphenhydramine increased AUC 2-fold; Coadministration with ketoconazole increased AUc by 70%. See https://pubmed.ncbi.nlm.nih.gov/24964257/
Page: 27.0
Tox targets
PubMed

PubMed

TitleDatePubMed
Hot flashes: aetiology and management.
2001
Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
2001
Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder.
2001
Hormone replacement in women with a history of breast cancer.
2001
Venlafaxine extended-release: a review of its use in the management of major depression.
2001
Separation anxiety disorder in children and adolescents: epidemiology, diagnosis and management.
2001
Do some antidepressants work faster than others?
2001
Pharmacology of rapid-onset antidepressant treatment strategies.
2001
Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies.
2001
Pharmacotherapy of generalized anxiety disorder.
2001
Venlafaxine in the treatment of postpartum depression.
2001 Aug
[Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
2001 Aug
Flushing in a menopausal woman taking venlafaxine.
2001 Aug
Topiramate in venlafaxine-induced visual hallucinations in an obese patient with a posterior cerebral artery infarction.
2001 Aug
Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features.
2001 Aug
S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
2001 Aug
S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
2001 Aug
Microdialysis in freely moving mice: determination of acetylcholine, serotonin and noradrenaline release in galanin transgenic mice.
2001 Aug 15
A review of the pharmacological and clinical profile of mirtazapine.
2001 Fall
Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms.
2001 Jul
Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
2001 Jul
[Depressive disorders and antidepressive therapy. A comparison of neurology practice and psychiatric clinic].
2001 Jul
Neuroimaging profiles and the differential therapies of depression.
2001 Jul
Functional brain circuits in major depression and remission.
2001 Jul
Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings.
2001 Jul
Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study.
2001 Jul
Venlafaxine-induced hair loss.
2001 Jul
Even low-dose treatment of venlafaxine may provoke recurrence of hypertension in an Asian patient?
2001 Jul-Aug
Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database.
2001 Jun
The health economic impact of antidepressant usage from a payer's perspective: a multinational study.
2001 Jun
The Stanley Foundation Bipolar Network. I. Rationale and methods.
2001 Jun
Antidepressant discontinuation (withdrawal) symptoms presenting as 'stroke'.
2001 Jun
Depression and anxiety disorders.
2001 Jun
Use of vancomycin silica stationary phase in packed capillary electrochromatography. II. Enantiomer separation of venlafaxine and O-desmethylvenlafaxine in human plasma.
2001 Jun 1
Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy.
2001 Mar
Attenuation of morphine dependence and withdrawal in rats by venlafaxine, a serotonin and noradrenaline reuptake inhibitor.
2001 May 25
Addition of olanzapine for treatment-resistant depression.
2001 Oct
Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study.
2001 Oct
Practitioner versus medication-expert opinion on psychiatric pharmacotherapy of mentally retarded patients with mental disorders.
2001 Oct 1
Once-daily venlafaxine extended release (XR) vs. fluoxetine for the treatment of depression.
2001 Sep
On-line capillary electrophoresis-electrospray mass spectrometry for the stereoselective analysis of drugs and metabolites.
2001 Sep
Antidepressants in social anxiety disorder.
2001 Sep
The pharmacoeconomics of venlafaxine in depression.
2001 Sep
The clinical, psychosocial, and pharmacoeconomic ramifications of remission.
2001 Sep
Effects of chronic tramadol on pre- and post-synaptic measures of monoamine function.
2001 Sep
The combined use of bupropion, lithium, and venlafaxine during ECT: a case of prolonged seizure activity.
2001 Sep
Long-term outcome after ECT for catatonic depression.
2001 Sep
High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum.
2001 Sep 25
[Changes in antidepressants consumption in the health area of Zamora from 1996 to 1999].
2001 Sep 30
Rapid high-performance liquid chromatographic measurement of venlafaxine and O-desmethylvenlafaxine in human plasma. Application to management of acute intoxications.
2001 Sep 5
Patents

Sample Use Guides

Major Depressive Disorder: for most patients, the recommended starting dose for Venlafaxine Extended Release Tablets is 75 mg/day, administered in a single dose. In the clinical trials establishing the efficacy of venlafaxine hydrochloride extended-release capsules in moderately depressed outpatients, the initial dose of venlafaxine was 75 mg/day. For some patients, it may be desirable to start at 37.5 mg/day for 4 to 7 days, to allow new patients to adjust to the medication before increasing to 75 mg/day. While the relationship between dose and antidepressant response for venlafaxine hydrochloride extended-release capsules has not been adequately explored, patients not responding to the initial 75 mg/day dose may benefit from dose increases to a maximum of approximately 225 mg/day. Dose increases should be in increments of up to 75 mg/day, as needed, and should be made at intervals of not less than 4 days, since steady state plasma levels of venlafaxine and its major metabolites are achieved in most patients by day 4. In the clinical trials establishing efficacy, upward titration was permitted at intervals of 2 weeks or more; the average doses were about 140 to 180 mg/day. It should be noted that, while the maximum recommended dose for moderately depressed outpatients is also 225 mg/day for venlafaxine hydrochloride immediate-release tablets, more severely depressed inpatients in one study of the development program for that product responded to a mean dose of 350 mg/day (range of 150 to 375 mg/day). Whether or not higher doses of Venlafaxine Extended Release Tablets are needed for more severely depressed patients is unknown; however, the experience with venlafaxine hydrochloride extended-release capsule doses higher than 225 mg/day is very limited. Social Anxiety Disorder (Social Phobia): the recommended dose is 75 mg/day, administered in a single dose. There was no evidence that higher doses confer any additional benefit.
Route of Administration: Oral
In Vitro Use Guide
In vitro radioligand binding studies were carried out in rat brain membranes to assess the affinity of various reuptake inhibitors for the serotonin (5-hydroxytryptamine, 5-HT) and the norepinephrine transporters using the selective ligands [3H]cyanoimipramine and [3H]nisoxetine, respectively. Venlafaxine, a dual 5-HT and norepinephrine reuptake inhibitor, displayed only a moderate affinity for the 5-HT transporter (Ki = 74 nM) and a very low affinity for the norepinephrine transporter (Ki = 1.26 microM). The relatively low affinities of venlafaxine contrast with its potent in vivo 5-HT and norepinephrine reuptake blocking properties. These results raise the possibility that the in vivo effects on the 5-HT and norepinephrine reuptake observed with venlafaxine may not be mediated solely by its binding to the [3H]cyanoimipramine and [3H]nisoxetine binding sites.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:14:00 UTC 2021
Edited
by admin
on Fri Jun 25 21:14:00 UTC 2021
Record UNII
7D7RX5A8MO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VENLAFAXINE HYDROCHLORIDE
EP   HSDB   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
NSC-745751
Code English
VENLAFAXINE HCL
Common Name English
VENLAFAXINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
VENLAFAXINE HYDROCHLORIDE [MI]
Common Name English
VENLAFAXINE HYDROCHLORIDE [WHO-DD]
Common Name English
VENLAFAXINE HYDROCHLORIDE [EP]
Common Name English
VENLAFAXINE HYDROCHLORIDE [VANDF]
Common Name English
VENLAFAXINE HYDROCHLORIDE [USAN]
Common Name English
VENLAFAXINE HYDROCHLORIDE [HSDB]
Common Name English
VENLAFAXINE HYDROCHLORIDE [MART.]
Common Name English
CYCLOHEXANOL, 1-(2-(DIMETHYLAMINO)-1-(4-METHOXYPHENYL)ETHYL)-, HYDROCHLORIDE
Systematic Name English
VENLAFAXINE (AS HYDROCHLORIDE)
Common Name English
EFFEXOR
Brand Name English
VENLAFAXINE HYDROCHLORIDE [JAN]
Common Name English
VENLAFAXINE HYDROCHLORIDE [USP-RS]
Common Name English
VENLAFAXINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
(+/-)-1-(.ALPHA.-((DIMETHYLAMINO)METHYL)-P-METHOXYBENZYL)CYCLOHEXANOL HYDROCHLORIDE
Common Name English
WY-45030
Code English
VENLAFAXINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Fri Jun 25 21:14:00 UTC 2021 , Edited by admin on Fri Jun 25 21:14:00 UTC 2021
Code System Code Type Description
MERCK INDEX
M11410
Created by admin on Fri Jun 25 21:14:00 UTC 2021 , Edited by admin on Fri Jun 25 21:14:00 UTC 2021
PRIMARY Merck Index
EVMPD
SUB05087MIG
Created by admin on Fri Jun 25 21:14:00 UTC 2021 , Edited by admin on Fri Jun 25 21:14:00 UTC 2021
PRIMARY
USP_CATALOG
1711268
Created by admin on Fri Jun 25 21:14:00 UTC 2021 , Edited by admin on Fri Jun 25 21:14:00 UTC 2021
PRIMARY USP-RS
EPA CompTox
99300-78-4
Created by admin on Fri Jun 25 21:14:00 UTC 2021 , Edited by admin on Fri Jun 25 21:14:00 UTC 2021
PRIMARY
RXCUI
235988
Created by admin on Fri Jun 25 21:14:00 UTC 2021 , Edited by admin on Fri Jun 25 21:14:00 UTC 2021
PRIMARY RxNorm
CAS
99300-78-4
Created by admin on Fri Jun 25 21:14:00 UTC 2021 , Edited by admin on Fri Jun 25 21:14:00 UTC 2021
PRIMARY
DRUG BANK
DBSALT000186
Created by admin on Fri Jun 25 21:14:00 UTC 2021 , Edited by admin on Fri Jun 25 21:14:00 UTC 2021
PRIMARY
PUBCHEM
62923
Created by admin on Fri Jun 25 21:14:00 UTC 2021 , Edited by admin on Fri Jun 25 21:14:00 UTC 2021
PRIMARY
NCI_THESAURUS
C29540
Created by admin on Fri Jun 25 21:14:00 UTC 2021 , Edited by admin on Fri Jun 25 21:14:00 UTC 2021
PRIMARY
FDA UNII
7D7RX5A8MO
Created by admin on Fri Jun 25 21:14:00 UTC 2021 , Edited by admin on Fri Jun 25 21:14:00 UTC 2021
PRIMARY
ChEMBL
CHEMBL637
Created by admin on Fri Jun 25 21:14:00 UTC 2021 , Edited by admin on Fri Jun 25 21:14:00 UTC 2021
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
ENANTIOMER -> RACEMATE
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY